Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Biocryst Pharmaceuticals Inc (BCRX)  
$6.31 0.13 (2.02%) as of 4:30 Fri 6/7


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 189,490,000
Market Cap: 1.20(B)
Last Volume: 3,291,159 Avg Vol: 4,448,162
52 Week Range: $4.13 - $8.81
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Biotechnology

Member Indexes:
    NASDAQ BIOTECHNOLOGY     NASDAQ COMPOSITE
    NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    : 16.9
Insider 6 Months    : 16.9
Insider 3/6 Months : 32.4
Guru Rank Number :  455
Guru Rank Value     : 3
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   BioCryst Pharmaceuticals is a commercial-stage biotechnology company that discovers oral, small-molecule medicines. Co. focuses on oral treatments for rare diseases. Co.'s drug/drug candidates include: ORLADEYO™ (berotralstat), an oral serine protease inhibitor targeting kallikrein that is being developed for the prevention of Hereditary Angioedema attacks; BCX9930, an oral factor D inhibitor for the treatment of complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitors for the treatment of fibrodysplasia ossificans progressive; and RAPIVAB® (peramivir injection), an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 183,601 183,601 183,601 183,601
Total Buy Value $1,048,338 $1,048,338 $1,048,338 $1,048,338
Total People Bought 10 10 10 10
Total Buy Transactions 10 10 10 10
Total Shares Sold 0 0 16,866 495,199
Total Sell Value $0 $0 $135,363 $5,999,241
Total People Sold 0 0 2 9
Total Sell Transactions 0 0 2 14
End Date 2024-03-10 2023-12-08 2023-06-09 2022-06-09

   
Records found: 475
  Page 16 of 19  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Baker Felix 10% Owner   –       –       •   2016-02-03 4 B $6.29 $573,311 I/I 91,187 12,824,440 1.5     -
   Baker Felix 10% Owner   –       –       •   2016-02-02 4 B $6.52 $598,360 I/I 91,728 12,733,253 1.5     -
   Barnes Alane P VP, General Counsel & Corp Sec   •       •      –    2016-01-29 4 OE $1.42 $27,503 D/D 19,368 85,057     -
   Baker Felix 10% Owner   –       –       •   2016-01-28 4 B $6.88 $172,015 I/I 25,000 12,641,525 1.5     -
   Baker Felix 10% Owner   –       –       •   2016-01-27 4 B $6.98 $441,971 I/I 63,345 12,616,525 1.5     -
   Powell Lynne Senior VP - CCO   •       •      –    2016-01-26 4 D $7.29 $28,067 D/D (3,850) 8,605     -
   Baker Felix 10% Owner   –       –       •   2016-01-22 4 B $7.00 $22,389 I/I 3,200 12,553,180 1.5     -
   Baker Felix 10% Owner   –       –       •   2016-01-21 4 B $7.29 $755,368 I/I 103,600 12,549,980 1.5     -
   Barnes Alane P VP, General Counsel & Corp Sec   •       •      –    2016-01-20 4 D $7.55 $19,622 D/D (2,599) 65,689     -
   Babu Yarlagadda S Senior VP - Drug Discovery   •       •      –    2016-01-20 4 D $7.55 $35,666 D/D (4,724) 142,334     -
   Sheridan William P Senior VP - CMO   •       •      –    2016-01-20 4 D $7.55 $40,460 D/D (5,359) 88,967     -
   Staab Thomas R Ii Senior Vice President and CFO   •       •      –    2016-01-20 4 D $7.55 $36,414 D/D (4,823) 145,093     -
   Stonehouse Jon P President & CEO   •       •      –    2016-01-20 4 D $7.55 $80,211 D/D (10,624) 665,702     -
   Stonehouse Jon P President & CEO   •       •      –    2016-01-20 4 OE $4.15 $99,998 D/D 24,096 676,326     -
   Baker Felix 10% Owner   –       –       •   2016-01-20 4 B $6.87 $362,171 I/I 52,695 12,446,380 1.5     -
   Staab Thomas R Ii Senior Vice President and CFO   •       •      –    2016-01-19 4 OE $1.42 $27,200 D/D 15,000 149,916     -
   Baker Felix 10% Owner   –       –       •   2016-01-19 4 B $7.12 $656,750 I/I 92,200 12,393,685 1.5     -
   Baker Felix 10% Owner   –       –       •   2016-01-15 4 B $7.45 $1,491,223 I/I 200,000 12,301,485 1.5     -
   Babu Yarlagadda S Senior VP - Drug Discovery   •       •      –    2016-01-01 4 D $10.32 $16,914 D/D (1,639) 147,058     -
   Barnes Alane P VP, General Counsel & Corp Sec   •       •      –    2016-01-01 4 D $10.32 $13,220 D/D (1,281) 68,288     -
   Sheridan William P Senior VP - CMO   •       •      –    2016-01-01 4 D $10.32 $21,476 D/D (2,081) 94,326     -
   Staab Thomas R Ii Senior Vice President and CFO   •       •      –    2016-01-01 4 D $10.32 $17,296 D/D (1,676) 134,916     -
   Stonehouse Jon P President & CEO   •       •      –    2016-01-01 4 D $10.32 $83,499 D/D (8,091) 652,230     -
   Staab Thomas R Ii Senior Vice President and CFO   •       •      –    2015-12-21 4 S $10.86 $33,145 D/D (3,052) 136,592     -
   Staab Thomas R Ii Senior Vice President and CFO   •       •      –    2015-12-17 4 S $10.49 $31,470 D/D (3,000) 139,644     -
  475 Records found
  Previous  10  11  12  13  14  15  16  17  18  19   
  Page 16 of 19
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us